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Background: Many Chinese patent medicines (CPMs) have been authorized by the Chinese State of Food and
Drug Administration for the treatment of the common cold. A number of clinical trials have been conducted and
published. However, there is no systematic review or meta-analysis on their efficacy and safety for the common
cold to justify their clinical use.
Methods: We searched CENTRAL, MEDLINE, EMBASE, SinoMed, CNKI, VIP, China Important Conference Papers
Database, China Dissertation Database, and online clinical trial registry websites for published and unpublished
randomized clinical trials (RCTs) of CPMs for the common cold till 31 March 2013. Revman 5.2 software was used
for data analysis with effect estimate presented as relative risk (RR) and mean difference (MD) with a 95%
confidence interval (CI).
Results: A total of five RCTs were identified. All of the RCTs were of high risk of bias with flawed study design and
poor methodological quality. All RCTs included children aged between 6 months to 14 years. Results of individual
trials showed that Shuanghuanglian oral liquid (RR 4.00; 95% CI: 2.26 to 7.08), and Xiaoer Resuqing oral liquid (RR
1.43; 95% CI: 1.15 to 1.77) had higher cure rates compared with antivirus drugs. Most of the trials did not report
adverse events, and the safety of CPMs was still uncertain.
Conclusions: Some CPMs showed a potential positive effect for the common cold on cure rate. However, due to
the poor methodology quality and the defects in the clinical design of the included RCTs, such as the lack of
placebo controlled trials, the inappropriate comparison intervention and outcome measurement, the confirmative
conclusions on the beneficial effect of CPMs for the common cold could not be drawn.
Keywords: Common cold, Traditional Chinese medicine, Chinese patent medicine, Randomized controlled trial,
Systematic reviewBackground
The common cold is one of the most widespread ill-
nesses, and is most caused by rhinoviruses [1]. On aver-
age, adults may have two to four annually [2], and
children may have six to ten colds a year [3]. Symptoms
of the common cold include runny nose, cough, sore
throat, fever and congestion.
Until now there is no proven treatment for the com-
mon cold. Previous studies did not show evidence of* Correspondence: jianping_l@hotmail.com
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and prescription of antibiotics for the common cold may
cause significant adverse effects [4,5]. While some alter-
native treatments were used for the common cold, there
was insufficient scientific evidence to support their use
[3]. Simple analgesics and antipyretics are used for
symptom control, such as ibuprofen [6] and acetamino-
phen/paracetamol [7].
Traditional Chinese medicine (TCM) has a long his-
tory of treating the common cold which can be traced
back to more than 2000 years ago, and many Chinese
herbs are believed to be effective. There are different cat-
egories of ‘cold’ in TCM, for example, 'wind-cold typetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ness type cold'. The categories are based on the cause and
symptoms of cold, and the medications are different for
different type of cold. Chinese patent medicine (CPM) is
an important component of Chinese herbs, and is widely
accepted by the Chinese people due to the convenience of
application. More than 300 CPMs have been approved by
the State Food and Drug Administration in China and
dozens are listed in the ‘China national essential drug list’.
It is an authorized list approved by the Ministry of Public
Health of China, and provides the basis for the medicine
used in medical institutions in China.
Until now, a number of clinical trials of CPM for the
common cold have been conducted and reported. The
aim of this systematic review is to provide evidence on po-
tential benefits and harms of CPM for the common cold.
Methods
Search strategy and study selection
We searched CENTRAL (2012, Issue 12), MEDLINE,
EMBASE, SinoMed, Chinese National Knowledge Infra-
structure (CNKI), Chinese VIP information (VIP), China
Important Conference Papers Database, and China
Dissertation Database from their inception to 31 March
2013. We also searched websites of Chinese clinical trial
registry (http://www.chictr.org/) and international clin-
ical trial registry by U.S. National Institutes of Health
(http://clinicaltrials.gov/) for ongoing registered clinical
trials. The following search terms were used individually
or combined: ‘cold’, ‘nasopharyngitis’, ‘acute viral rhino-
pharyngitis’, ‘acute coryza’, ‘shang feng (cold in Chinese)’,
‘wai gan (cold in Chinese)’, and ‘feng han (cold in Chinese)’,
‘Chinese Traditional’, ‘Chinese patent medicine’, ‘Oriental
Traditional’, ‘herb’, ‘herbal medicine’, ‘clinical trial’, and ‘ran-
domized controlled trial’. The search strategy of CNKI
was listed in Appendix 1.
To ensure accuracy, two authors conducted the litera-
ture searching, study selection and data extraction inde-
pendently, and the final results were double checked.
Inconsistencies were resolved by negotiation or seeking
third-party settlement. We extracted the following data:
authors, title of study, year of publication, study size, age
and sex of the participants, details of methodological in-
formation, name and component of Chinese patent
medicines, treatment process, details of the control in-
terventions, outcomes, and adverse effects.
Inclusion criteria
Parallel randomized controlled trials (RCTs) of CPMs
for the treatment of the common cold were included.
There was no limitation on age or sex. Colds caused by
influenza, acute bronchitis developing from a case of
the common cold, and upper respiratory tract infection
caused by bacteria were excluded. We restricted CPMsas those listed in ‘China national essential drug list 2012’.
CPMs is defined as those mainly produced by modern
manufacturing methods. These are produced as different
preparations of herbal medicines such as powder, granule,
pastille, tablet, and capsule.
The comparison interventions included no treatment,
placebo or conventional medication. Combined therapy
of CPMs and other interventions compared with other
interventions was also included. The outcome measures
were fever clearance time (the time between commen-
cing treatment and temperature returning to normal),
cure rate, time to resolution of individual symptoms
(cough, nasal congestion, nasal drainage and sore throat)
and adverse events. Publications that report same data
were regarded as multiple publications and were ex-
cluded. There was no restriction on language and publi-
cation type.
Trial quality assessment
Two authors evaluated the quality of included trials in-
dependently. We used the Cochrane 'Risk of bias' tool
for assessing bias with consideration of the following as-
pects: random sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding of
outcome assessment, incomplete outcome data, and se-
lective reporting [8]. The quality of all the included trials
was evaluated as to be low/unclear/high risk of bias ac-
cording to how these above criteria were met.
Data analysis
We used the relative risk (RR) with 95% confidence in-
tervals (CI) for dichotomous data, and mean difference
(MD) with 95% CI for continuous outcomes. Revman
5.2 software was used for data analyses. For RCTs with
good homogeneity on study design, participants, inter-
ventions, control, and outcome measures, meta-analysis
was planned to be conducted. If at least ten trials were
available for a meta-analysis, we would assess for the




A total of 33 CPMs were listed in ‘China national essen-
tial drug list 2012’ for the treatment of the common
cold, and clinical studies of the 33 CPMs were searched
from the above eight databases and two clinical trials
registry websites. A flow chart depicts the search process
and study selection (Figure 1). After primary searches,
83 citations were identified, and the majority was ex-
cluded due to obvious ineligibility from reading title/
abstract. Full text papers of 31 studies were retrieved. At
last, a total of 5 RCTs including 5 different CPMs [9-13]
were included. These 5 CPMs were Chaihu injection [9],
Figure 1 Flow chart of included studies in this systematic review.
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liquid [11], Xiaoer Baotaikang granules [12], and Xiaoer
Resuqing oral liquid [13]. One four-armed RCT [9] was
included which compared Chaihu injection given by acu-
point block, Chaihu injection given by intramuscular in-
jection, saline given by acupoint block, and ribavirin given
by intramuscular injection. The compositions and indica-
tions of the 5 CPMs included in the review were shown
in Table 1. We collected the data of group that received
Chaihu injection given by intramuscular injection andTable 1 Compositions and indications of CPMs included in th
Name of CPMs Compositions
Chaihu Injection Radix Bupleuri
Ganmao Qingre granules Schizonepeta tenuisfolia Briq, Herba Menth
haplocalyx., Radix Saposhnikoviae, Radix B
Folium Perillae, Radix Pueraria lobata (Willd
Radix Platycodonis, Semen Armeniacae Am
Radix Angelica dahuricae, Herba corydalis
Bungeanae, Rhizoma Phragmites commun
Shuanghuanglian oral liquid Radix Scutellaria baicalensis Georgi, Flos Lo
Fructus Forsythiae
Xiaoer Baotaikang granules Fructus Forsythiae, Radix Rehmanniae, Bup
marginatum, Radix Scrophulariae, Folium
Bulbus Fritillaria thunbergii Miq., Herba Tar
Baphicacanthus cusia (Nees) Bremek, Onos
Radix Platycodonis, Semen Raphani, Radix
Glycyrrhizae
Xiaoer Resuqing oral liquid Radix Bupleuri, Radix Scutellaria baicalensis
Radix Isatidis, Radix Pueraria lobata (Willd)
Flos Lonicerae, Cornu Bubali, Fructus Forsy
Radix et Rhizoma Rheigroup that received ribavirin given by intramuscular
injection. The search for ongoing registered trials iden-
tified no trial.
The characteristics of included trials are listed in
Table 2. A total of 633 participants with the common
cold were involved with the average number of 127 per
trial, ranging from 60 to 253. All RCTs included children
aged between 6 months to 14 years. One RCT [9] did
not provide the age of included children. All RCTs in-
cluded outpatients. Three RCTs [9,12,13] diagnosed thee review for the common cold
Indications






For the wind-cold cold, headache, fever, aversion to cold,
body pain, runny nose, cough and dry throat.
nicerae, For the cold induced by external contraction wind-heat,





For children with external contraction wind-heat, such as




For children with cold induced by external contraction
wind-heat, such as fever, headache, throat swelling and
pain, nasal congestion and nasal discharge, cough,
dry stool.
Table 2 The characteristics of included RCTs
Name of CPMs Study
ID
Diagnostic criteria TCM pattern
differentiation
Patients Comparator Outcomes Adverse
events
Chaihu injection
(acupoint block in T1
or intramuscular
injection in T2)
Lv [9] Guiding principle of clinical
research on new drugs of
traditional Chinese
Medicine*
Not reported N = 253 (100 in T1, 52 in T2,
50 in C1, and 51 in C2); M/



















N = 60 (30/30); M/F: 18/12












Not reported N = 100 (50/50); M/F: not











Criteria of diagnosis and





N = 100 (50/50); M/F: not
reported; Age: 4.28 ±
3.37 years in T, and 4.56 ±







Li [13] Diagnostic criteria for high
fever of external contraction
(Waigan Gaore in TCM
syndroms)*
Not reported N = 120 (65/55); M/F: 75/45;





*Issued by the State Administration of Traditional Chinese Medicine of the People’s Republic of China.
Figure 2 Risk of bias summary about each risk of bias item for
each included study.
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tration of Traditional Chinese Medicine of the People’s
Republic of China, one RCT [10] diagnosed the common
cold by criteria from textbook, and one RCT [11] diag-
nosed the common cold based on Clinical symptoms
and laboratory test results. One trial included wind-cold
type of common cold [10], one trial included wind-heat
type of common cold [13], while the other three trials
did not provide information on patients’ syndrome dif-
ferentiation. The total treatment duration ranged from 3
to 5 days. The control interventions included antibiotics,
antivirus drugs, and antipyretic and analgesic drugs. No
placebo controlled trial was identified. The reported out-
come measurements included fever clearance time, cure
rate, and adverse events.
Methodological quality
All of the included trials were assessed to be of generally
poor methodological quality. All the RCTs mentioned
that ‘participants were randomized into groups’, but did
not report the detailed methods for sequence generation.
We contacted the authors of the included RCTs, one
trial [11] claimed that they drew lots to assign the partic-
ipants; the other trials did not respond to our inquiry.
Allocation concealment and blinding was not mentioned
in any RCT. And because of the different formulation of
CPMs and control intervention, it was not likely to con-
duct blinding either to investigator or to patients. No
trial reported drop-out or withdrawals, or mentioned
intention-to-treat analysis. Selective reporting was un-
clear because we could not access to the protocols of in-
cluded RCT. All the included RCTs did not register in
relevant authoritative websites prior to the start of thestudy. The risk of bias summary about each risk of bias
item for each included study is shown in Figure 2.
Effect estimates
1. 1 CPM vs. antivirus drugs
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One RCT [9] reported the effect of Chaihu injection given
by intramuscular injection on defervescence. Results
showed that there was no difference between Chaihu
and ribavirin injection on fever clearance time (hours)
(MD −0.99, 95% CI: −6.31 to 4.33).
Cure rate
Three trials [9,11,13] compared CPMs with antivirus
drugs on cure rate. Results showed that there was no dif-
ference between Chaihu injection and ribavirin injection
(RR 0.78, 95% CI: 0.22 to 2.76), Shuanghuanglian oral li-
quid had higher cure rate compared with ribavirin injec-
tion (RR 4.00; 95% CI: 2.26 to 7.08), and Xiaoer Resuqing
oral liquid had higher cure rate compared with moroxy-
dine tablets (RR 1.43; 95% CI: 1.15 to 1.77) (Figure 3).
Meta-analysis was not performed due to the hetero-
geneity in experimental and control interventions among
included trials.
2. CPM vs. antipyretic and analgesic drugs
Cure rate
One trial [10] compared CPMs with antipyretic and anal-
gesic on cure rate. Results showed that there was no dif-
ference between Ganmao Qingre granules and pediatric
paracetamol on cure rate (RR 1.31; 95% CI: 0.78 to 2.19).
3. CPM vs. antibioticsFigure 3 Forest plot of comparison of CPM with antivirus drugs on cuCure rate
One trial [12] compared CPMs with antibiotics on cure
rate. Results showed that Xiaoer Baotaikang granules
had higher cure rate compared with amoxicillin granules
(RR 2.67; 95% CI: 1.56 to 4.55).
Adverse events
One RCT [11] stated that no adverse event was identi-
fied. The remaining four RCTs did not mention whether
they monitored the adverse events.
Funnel plot
We did not conduct funnel plots due to the inadequate
number of included trials.
Discussion
In this review, we found out that only 5 out of 33 CPMs
recommended in the ‘China national essential drug list’
for the common cold had scientific clinical evidence to
support their use. However, due to the poor method-
ology quality and defects in the clinical design, such as
lack of placebo control, the inappropriate comparison
intervention and outcome measurement, the confirma-
tive conclusions on the beneficial effect of CPMs for the
common cold could not be drawn. In addition, all the
included RCTs enrolled children aged between 6 months
to 14 years. The effect of CPMs for adult patients could
not be drawn from this review.re rate.
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‘China national essential drug list 2012’. The reason was
that ‘China national essential drug list’ was the autho-
rized list approved by the Ministry of Public Health of
China and was provided as the basis for the medicine
used in medical institutions in China. However, although
33 CPMs were recommended in the ‘China national es-
sential drug list 2012’ for the common cold, only 5 were
found have previous clinical evidence. Our results re-
vealed the lack of evidence for clinical use and policy
making of TCM in China.
We thought the possible reasons of the inconclusive
therapeutic effect of the above CPMs for the common
cold might be as follows: Firstly, all the included trials
were assessed to be of poor methodology quality. No
RCT stated randomization procedure except one [11];
the rest just mentioned that ‘the patients were random-
ized into two groups’ without providing detailed infor-
mation to judge whether randomization was conducted
properly. Allocation concealment and blinding was not
mentioned in any RCT. And because of the different for-
mulation of CPMs and control intervention, it is not
likely to be possible to achieve blinding either to investi-
gator or to patients. Therefore, both the investigator and
the patients know exactly if they are taking CPMs or
conventional medicines. In China, people generally have
strong expectations of benefit from CPMs than conven-
tional medicine due to the deeply rooted belief in TCM.
We believed that these preferences and expectations
might positively bias participants' later responses, espe-
cially when the outcome measurement was a more sub-
jective index such as cure rate. Fever clearance time, in
contrast, was an objective outcome and was less likely to
be affected by participants’ expectations. However, only
one trial reported the data and the result showed that
there was no difference between Chaihu and ribavirin
injection on fever clearance time. Previous studies had
proven that methodologically poorly designed trials
would demonstrate larger differences between experi-
mental and control groups than those conducted rigor-
ously [14,15], therefore, we should use caution when
interpreting the the small improvements in outcomes in
our review.
Secondly, there was lack of placebo control in the in-
cluded RCTs. The common cold is a mild and self-
limiting disease and does not have the proven effective
intervention. For this kind of disease, we think a placebo
controlled trial is the best choice. In this review, no
placebo controlled trial was identified, while the abuse
of antibiotics and misuse of antiviral deserved our con-
cern. In our review, the control interventions included
antibiotics, antivirus drugs, and antipyretic and analgesic
drugs. It is known that antibiotics have no effect against
viral infections and thus have no effect against theviruses that cause the common cold. However, in China,
antibiotics are quite commonly used for the common
cold in clinical practice even if in most of the cases there
is no sign of complications of bacterial infection. Some
of the reasons that antibiotics are so commonly pre-
scribed include people's expectations for them, physi-
cians' desire to help, and the difficulty in excluding
complications that may be amenable to antibiotics. In
our review, one RCT [12] used amoxicillin granules as
the control intervention, however, it did not report
whether there were simultaneous bacterial infections.
There are also no effective antiviral drugs for the com-
mon cold that have been proven by clinical trials [3]. In
this review, two antiviral medicines (ribavirin and mor-
oxydine) were used as the control intervention. In the
UK and USA, ribavirin is only used for severe respiratory
infections such as respiratory syncytial virus bronchio-
litis in infants and children or severe acute respiratory
syndrome (SARS) (or for chronic hepatitis) [16-18].
Moroxydine is originally developed as an influenza treat-
ment. In our review, all the patients were enrolled as
having simple the common cold, no data was provided
on whether the patients was having complications or in
high risk categories that needs to be treated by ribavirin
and moroxydine, and from the average short treatment
period (3 to 5 days), it was less likely that these treat-
ments were for severe respiratory infections. It has been
proved that antibiotics could cause significant adverse
effects in adults when given for the common cold [5],
and the adverse events of ribavirin was found in treating
SARS [19]. Therefore, the risk-benefit of using drugs
such as antibiotics and antiviral drugs deserves more at-
tention for future studies of the common cold.
Thirdly, the outcome measurements of the included
RCTs were ambiguous and susceptible to bias. All RCTs
used ‘cure rate’ as the outcome measurement. It was a
composite outcome including the clinical symptom dis-
appearance and abatement of fever. It was not an inter-
nationally recognized outcome measurement but was
commonly used in Chinese TCM trials. However, subtle
differences existed in the criteria or cut point in different
trials, which made it difficult to interpret the effects of
CPMs. Moreover, this outcome measurement was sus-
ceptible to subjective bias when assessing the improve-
ment of clinical symptoms. The included RCTs did not
state that they have independent outcome assessors. We
believed that the outcome assessors were the investiga-
tors themselves. This approach was very easy to intro-
duce bias, especially for subjective outcome such as
cure rate. Another thing worth noting in this review is
that Chinese TCM researchers pay too much attention
on the body temperature. Even for the composite out-
come measurement of ‘cure rate’, body temperature was
always a vital component, though different definitions
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of the common cold and might not be the primary one
because the common cold caused a range of symptoms
such as coughing, sore throat, runny nose and sneezing.
Future TCM researchers should be encouraged to use well
validated outcome measurements and to consider all the
related symptoms, for example, patient-reported daily
symptom diary including symptom variables.
Finally, the diagnostic criteria used in the included
RCTs were quite diverse. All diagnostic criteria were
based on clinical symptoms and laboratory test results.
No trial used virological examination. Possibility existed
that participants with other acute respiratory infections
might have been misdiagnosed as having simple com-
mon cold and were recruited. In addition, the report of
patients’ syndrome differentiation ('bianzheng' in TCM,
a specific diagnosis in TCM) was inadequate. In the
practice of TCM, herbal preparations should match the
type of syndrome differentiation, and this was thought
to be the advantages of TCM. Chinese medicine practi-
tioners believed that treating patients without syndrome
differentiation would impair the advantages of Chinese
herbs. In our review, only two trials reported patients’
syndrome differentiation, the relationship between the
efficacy and the pattern of the common cold could not
be investigated due to the lack of a group with the op-
posite pattern of syndromes. In addition, no trial re-
ported whether they had quality control for the herbal
preparations or for the herbal products.
The reporting of adverse events was not adequate. Only
one RCT [11] stated that no adverse event was identified.
The remaining four RCTs did not mention whether they
monitored the adverse events. Conclusions about the
safety of CPMs cannot be drawn from this review.
In our review, all the included trials were conducted in
China and published in Chinese, no English paper was
identified, and no 'negative' study was included. We did
not conduct funnel plots due to the inadequate number
of included trials, however, possibility of publication bias
could not be excluded considering the fact that all the
trials claimed positive effect favoring CPMs though some
of the trials turned out to be negative when analyzed by
standard statistical techniques using risk ratios or mean
differences.
We noticed that a systematic review that assessed the
effect of Chinese medicinal herbs for the common cold
has been published [20]. In this review, a total of 17 tri-
als were included. However this review included both
CPMs and individually prescribed herbal formulae.
Most of them were not the recommended CPMs listed
in the ‘China national essential drug list 2012’ that was
the accepted reference point for the medicines used in
medical institutions in China. The CPMs in this review
did not include our CPMs. We thought the reasonmight be the difference in the search strategy and the
date of searching. Most of our included RCT were con-
ducted after 2010 which is beyond the searching date of
this previous review.
In summary, we could not take the beneficial effect of
CPMs for the common cold as a confirmative conclu-
sion. For mild and self-limitating disease like the com-
mon cold, a placebo controlled trial is the best study
design to determine the efficacy of intervention. In
addition, future TCM researchers should place more em-
phasis to the selection of outcome measurement, control
intervention, and report trials according to the CON-
SORT Statement [21].
Conclusions
Some CPMs showed a potential positive effect for the
common cold on cure rate. However, due to the poor
methodology quality and the defects in the clinical design
of the included RCTs, such as the lack of placebo con-
trolled trials, the inappropriate comparison intervention
and outcome measurement, the confirmative conclusions
on the beneficial effect of CPMs for the common cold
could not be drawn.
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Written informed consent was obtained from the patient
for the publication of this report and any accompanying
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Appendix 1: CNKI search strategy
1. exp Randomized Controlled trials/all subheadings
2. Random*
3. 1 or 2
4. exp traditional Chinese medicine/all subheadings
5. exp Chinese patent medicine/all subheadings
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